TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$33.94
-0.35 (-1.02%)
▼
5d:
-5.3%
30d:
+4.75%
90d:
-1.37%
HOLD
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA is fairly valued with market pricing in 1.2% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: TEVA is fairly valued with market pricing in 1.2% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.69
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$40.17
15.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $33.94, which is considered fair relative to its 30-day fair value range of $31.30 to $35.53. The stock's valuation (Forward PE: 11.0) is in line with its historical norms (10.7). At these levels, the market is pricing in 1.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is showing sideways momentum. The price is currently testing key support at $33.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $40.27 (+17.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is showing sideways momentum. The price is currently testing key support at $33.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $40.27 (+17.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$31.30 -
$35.53
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($40.27)
- NEUTRAL: Market pricing in 1.2% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$31.30 -
$35.53
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$33.61
Resistance Level
$36.99
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.04
Wall Street Target
$40.27
(+17.4%)
Revenue Growth (YoY)
2.3%
Earnings Growth (YoY)
72.2%
Profit Margin
9.0%
Valuation Premium vs History
+1.2% premium
PE vs Historical
11.0 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.2%
(market-implied from PE analysis)
1-Year Target
$34.70
(+1%)
2-Year Target
$35.12
(+2%)
3-Year Target
$35.54
(+4%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$34.43
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 29.7%)
$149.53
(+336%)
Base:
(SPY PE: 11.0, Growth: 29.7%)
$74.83
(+118%)
Bear:
(PE: 9.4, Growth: 29.7%)
$63.61
(+86%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 25.37 | Current EPS (TTM): $1.34
Bull Case
$74.79
(+118%)
Analyst growth 100.0%, PE expands to 27.9
Base Case
$67.99
(+98%)
Market implied 100.0%, PE stable at 25.4
Bear Case
$23.12
(-33%)
Severe decline -20.0%, PE contracts to 21.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 18, 2026 1:48 PM ET
Data refreshes hourly during market hours. Next update: 2:48 PM
Data refreshes hourly during market hours. Next update: 2:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 55 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 54 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
